Darifenacin provides clinically meaningful quality of life improvements in patients with overactive bladder assessed by minimal important difference (MID) analysis
Reese P1, Niecko T2, Huels J3, Kelleher C4 1. Reese Associates Consulting, LLC, Cary, USA, 2. Durham, NC, USA, 3. Novartis Pharma AG, Basel, Switzerland, 4. Department of Obstetrics and Gynaecology, Guy’s & St Thomas’ Hospital Trust, London, UK
|
|
Abstract 326
|
|
|
Non Discussion Posters
Scientific Non Discussion Poster Session 17
|
|
|